How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Narcolepsy Market
- By Treatment Type: Stimulants, Sodium Oxybate, Antidepressants, Pitolisant, Solriamfetol
- By Symptom Targeted: Excessive Daytime Sleepiness, Cataplexy, Hypnagogic Hallucinations, Sleep Paralysis
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- By Patient Age Group: Pediatric, Adult, Geriatric
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Stimulants leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 258 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.162 →
- 11 Company Profiles 10 players: SWOT & benchmarking p.170 →
Full report · locked preview
Everything inside the Narcolepsy Market report
A complete, evidence-based study - 11 chapters and 108 sections covering market size, segmentation across 4 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Symptom Targeted 4
Distribution Channel 3
Patient Age Group 3
Companies profiled
Jazz Pharmaceuticals
Takeda Pharmaceutical Company
Biogen
Eisai Co. Ltd.
Sunovion Pharmaceuticals (a subsidiary of Sumitomo Dainippon Pharma)
Axsome Therapeutics
Harmony Biosciences
Avadel Pharmaceuticals
Idorsia Pharmaceuticals
Lundbeck
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Jazz Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Takeda Pharmaceutical Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Biogen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Eisai Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sunovion Pharmaceuticals (a subsidiary of Sumitomo Dainippon Pharma)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Axsome Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Harmony Biosciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Avadel Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Idorsia Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Lundbeck
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,029M by 2033 · 10.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Stimulants44.6
- Sodium Oxybate11.6
- Antidepressants17.6
- Pitolisant10.1
- Solriamfetol16.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$771.9M → $1,591M · 9.5%
Europe$538.0M → $1,140M · 9.8%
Asia Pacific$491.2M → $1,070M · 10.2%
Latin America$304.1M → $694.3M · 10.9%
Middle East and Africa$233.9M → $452.0M · 8.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.982026
10.002027
10.022028
10.032029
10.052030
10.052031
10.072032
10.082033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Jazz Pharmaceuticals10.3
- Takeda Pharmaceutical Company28.4
- Biogen6.1
- Eisai Co. Ltd.11.0
- Sunovion Pharmaceuticals (a subsidiary of Sumitomo Dainippon Pharma)10.4
- Axsome Therapeutics5.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type23.7%
Symptom Targeted31.3%
Distribution Channel21.0%
Patient Age Group23.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.2
- Europe23.0
- Asia Pacific21.6
- Latin America14.0
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals | 94 | 83 | 85 | 90 | 91 | 82 | 88 |
| Takeda Pharmaceutical Company | 88 | 77 | 73 | 89 | 87 | 71 | 81 |
| Biogen | 72 | 83 | 73 | 68 | 77 | 87 | 77 |
| Eisai Co. Ltd. | 65 | 69 | 68 | 58 | 82 | 66 | 68 |
| Sunovion Pharmaceuticals (a subsidiary of Sumitomo Dainippon Pharma) | 60 | 73 | 63 | 70 | 64 | 75 | 68 |
| Axsome Therapeutics | 63 | 58 | 68 | 69 | 57 | 46 | 60 |
| Harmony Biosciences | 51 | 41 | 43 | 52 | 49 | 44 | 47 |
| Avadel Pharmaceuticals | 53 | 36 | 49 | 40 | 46 | 36 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Jazz Pharmaceuticals
- Takeda Pharmaceutical Company
- Biogen
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Takeda Pharmaceutical Company | ✓ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Biogen | − | ✓ | ◐ | ◐ | ◐ | ✓ |
| Eisai Co. Ltd. | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Sunovion Pharmaceuticals (a subsidiary of Sumitomo Dainippon Pharma) | ◐ | ✓ | ◐ | − | ◐ | ✓ |
| Axsome Therapeutics | ◐ | − | ✓ | − | ◐ | − |
| Harmony Biosciences | ◐ | − | ◐ | − | − | − |
| Avadel Pharmaceuticals | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Jazz Pharmaceuticals88
2Takeda Pharmaceutical Company81
3Biogen77
4Eisai Co. Ltd.68
5Sunovion Pharmaceuticals (a subsidiary of Sumitomo Dainippon Pharma)68
6Axsome Therapeutics60
7Harmony Biosciences47
8Avadel Pharmaceuticals43
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Jazz PharmaceuticalsTakeda Pharmaceutical Company
Challenger3
Strong scale, closing on the leaders.
BiogenEisai Co. Ltd.Sunovion Pharmaceuticals (a subsidiary of Sumitomo Dainippon Pharma)
Contender1
Focused players with pockets of strength.
Axsome Therapeutics
Niche2
Specialists in a single segment or region.
Harmony BiosciencesAvadel Pharmaceuticals
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Narcolepsy Market — a $265M beachhead inside a $4.80B market.
Beachhead (SOM)$265Mobtainable near-term
Serviceable (SAM)$1.78Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Stimulants
Best fit — highest urgency & budget in Treatment Type.
Economic buyer81 fit
Sodium Oxybate
Strong fit — clear ROI and a fast path to value.
End user69 fit
Antidepressants
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Symptom Targeted & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Distribution Channel
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Narcolepsy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified23%
Evaluation11%
Closed-won6%
$9.3KCAC
$45KLTV
4.8:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Narcolepsy Market is a durable-growth opportunity — $8.33B by 2033, compounding at 8.2%.
TAM · 2025$4.43Btoday
TAM · 2033$8.33Bforecast
CAGR8.2%2027–2033
Cumulative$55.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.33BTotal addressable market
SAM$3.11BServiceable available market
SOM$624MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.2% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.33BLarge & growingTAM by 2033 at 8.2% CAGR
$3.11BServiceable nowreachable with today’s model
$624MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.50BBear5.3% CAGR
$8.33BBase8.2% CAGR
$10.7BBull10.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Symptom Targeted optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Narcolepsy Market — a $2.24B market by 2033. Plan: grow share from 5.8% to 11.9%.
Market size · 2033$2.24Btotal addressable
Market CAGR5.1%2027–2033
Target share11.9%from 5.8% today
Revenue ambition$266Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.8% | 11.9% | At risk |
| Revenue | $140M | $266M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 35.8% | 45.4% | Behind |
| Customer retention | 91.1% | 93.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Symptom Targeted capability
A defensible second engine — invest in Symptom Targeted to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Symptom Targeted
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $30M capacity & capability investment
- Greenlight bolt-on M&A in Symptom Targeted
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Narcolepsy Market conversation — a $11.8B market you can size, segment and defend in minutes.
Market size · 2033$11.8Btotal opportunity
Growth10.3%CAGR to 2033
Addressable buyers942+accounts in scope
Typical ROI7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7×return on cost, year one
< 2 mopayback period
$54K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Jazz PharmaceuticalsTakeda Pharmaceutical CompanyBiogenEisai Co. Ltd.Sunovion Pharmaceuticals (a subsidiary of Sumitomo Dainippon Pharma)Axsome TherapeuticsHarmony BiosciencesAvadel Pharmaceuticals+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Narcolepsy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Narcolepsy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Nasal Drug Delivery Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportNatural Antimicrobials Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportNecrotising Enterocolitis Market
Market size, share, segmentation and regional forecast.
$646M market · 2025 base year
View reportNecrotizing Fasciitis Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportNeedle Biopsy Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportNephroblastoma Treatment Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportNerve Regeneration Market
Market size, share, segmentation and regional forecast.
$823M market · 2025 base year
View reportNeuropsychiatric Disorders And Treatment Market
Neuropsychiatric Disorders And Treatment Market is valued at USD 122.4 Billion in 2025 and is e…
$122.4B market · 2025 base year
View reportInsect Genomic DNA Extraction Kit Market
Market size, share, segmentation and regional forecast.
$396M market · 2025 base year
View reportNeurosyphilis Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportNon-Destructive Medical Technologies Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportNon-Invasive Monitoring Device Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.